RayKnowChina Research Map
Shortlist

LuzhouSouthwest Medical University

Affiliated Hospital of Southwest Medical University

西南医科大学附属医院

Listed for 27 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Affiliated Hospital of Southwest Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌15 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌12 papers led
  3. Hepatocellular carcinoma肝细胞癌97 papers led
  4. Stomach cancer胃癌39 papers led
  5. Retinoblastoma视网膜母细胞瘤1 paper led
  6. Chordoma脊索瘤1 paper led
  7. Osteosarcoma骨肉瘤20 papers led
  8. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  9. Neuroblastoma神经母细胞瘤1 paper led
  10. Ewing sarcoma尤文肉瘤3 papers led
  11. Multiple myeloma多发性骨髓瘤10 papers led
  12. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病2 papers led
  13. Aplastic anaemia再生障碍性贫血2 papers led
  14. Beta thalassaemiaβ 地中海贫血3 papers led
  15. Fanconi anaemia范可尼贫血1 paper led
  16. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎3 papers led
  17. Takayasu arteritis大动脉炎1 paper led
  18. Hepatic echinococcosis肝包虫病1 paper led
  19. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  20. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病1 paper led
  21. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  22. Behçet disease白塞病1 paper led
  23. Alport syndromeAlport 综合征1 paper led
  24. IgA nephropathyIgA 肾病3 papers led
  25. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  26. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
  27. Familial adenomatous polyposis家族性腺瘤性息肉病2 papers led

Not listed for: Hepatoblastoma, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 15 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
15
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 4420222023: 4420232024: 3320242025: 332025

1 hospital in Luzhou for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & AIInduction / concurrent chemotherapyRadiotherapy technique
Departments in papersENT / head & neck surgeryMedical oncologyRadiology / nuclear medicine
Papers it led15
  1. Serum HOTTIP expression is upregulated in nasopharyngeal carcinoma patients and predicts poor prognosis.2025Brazilian journal of otorhinolaryngologyFree full text
  2. Construction of a prognostic model for nasopharyngeal carcinoma based on serum exosomal circular RNAs and analysis of immune microenvironment.2025Clinical and experimental medicineFree full text
  3. Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT for tumor staging and primary tumor volume delineation in patients with nasopharyngeal carcinoma.2025Scientific reportsFree full text
  4. Development of a neoadjuvant chemotherapy efficacy prediction model for nasopharyngeal carcinoma integrating magnetic resonance radiomics and pathomics: a multi-center retrospective study.2024BMC cancerFree full text
  5. Comparison of [18F]FDG and [68 Ga]pentixafor PET/CT in Nasopharyngeal Carcinoma.2024Molecular imaging and biology
  6. Comprehensive analysis revealed P4Hs as new biomarkers for prognosis and immunotherapy in head and neck cancer.2024Scientific reportsFree full text
  7. Cytoplasmic poly(A)-binding protein 1 (PABPC1) is a prognostic biomarker to predict survival in nasopharyngeal carcinoma regardless of chemoradiotherapy.2023BMC cancerFree full text
  8. Reducing Target Volumes of Intensity Modulated Radiation Therapy After Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Long-Term Results of a Prospective, Multicenter, Randomized Trial.2023International journal of radiation oncology, biology, physicsRCT
  9. Long non-coding RNA HOTTIP exerts an oncogenic function by regulating HOXA13 in nasopharyngeal carcinoma.2023Molecular biology reportsFree full text
  10. HOXA13 promotes the proliferation, migration, and invasion of nasopharyngeal carcinoma HNE1 cells by upregulating the expression of Snail and MMP-2.2023Scientific reportsFree full text
  11. Development of a Radiotherapy Localisation Computed Tomography-Based Radiomic Model for Predicting Survival in Patients With Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy Following Induction Chemotherapy.2022Cancer control : journal of the Moffitt Cancer CenterFree full text
  12. Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma.2022Scientific reportsFree full text
  13. Prognostic significance of systemic immune-inflammation index in patients with nasopharyngeal carcinoma: a meta-analysis.2022Systematic reviewsFree full text
  14. Minimally Invasive Surgery for Early-Stage Nasopharyngeal Carcinoma.2022The Journal of craniofacial surgeryFree full text
  15. FANCD2 knockdown with shRNA interference enhances the ionizing radiation sensitivity of nasopharyngeal carcinoma CNE-2 cells.2021Neoplasma
All its trials on ClinicalTrials.gov, any status3
  1. The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPCStatus unknownNCT04830267Study sitePhase 2Start 2021-03
  2. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08
  3. Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal CarcinomaStatus unknownNCT02211677Study siteStart 2014-08
More papers found outside PubMed (not counted)9
  1. A Deep-Learning Model Integrating Multi-Modality Data for Predicting the Recurrence of Nasopharyngeal Carcinoma2025International Journal of Radiation Oncology*Biology*Physicsarticle
  2. DoseNet: Dose-adaptive prediction of the parotid glands deformation for radiotherapy planning2025Image and Vision Computingarticle
  3. Omission of concurrent chemotherapy in and out of a phase III randomized controlled trial for stage II nasopharyngeal carcinoma.2025Journal of Clinical Oncologyconference-abstract
  4. The value of imaging techniques based on enhanced magnetic resonance imaging in the diagnosis and prediction response of radiotherapy for nasopharyngeal carcinoma2025International Journal of Radiation Researcharticle
  5. HOXA13 promotes the proliferation, migration, and invasion of nasopharyngeal carcinoma HNE1 cells by upregulating the expression of Snail and MMP-22022Laryngo-Rhino-Otologiearticle
  6. Interim Results of a Prospective, Randomized, Multicenter, Phase 3 Study of the Efficacy of Increasing the Cycles of Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma2022International Journal of Radiation Oncology*Biology*Physicsarticle
  7. The global, regional, and national burden of nasopharyngeal carcinoma and its attributable risk factors in 204 countries and territories, 1990–20192022Figsharedataset
  8. Correlation Between Immune Function Status and EBV DNA in Patients with Nasopharyngeal Carcinoma and Their Influence on Prognosis2021DOAJ (DOAJ: Directory of Open Access Journals)article
  9. EBV-positive LMP1-mediated Signal Pathway in Nasopharyngeal Carcinoma2021Learning & Educationarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 12 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
12
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 6620232024: 2220242025: 222025

1 hospital in Luzhou for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesEarly detection & endoscopyMolecular markers & genomicsRadiotherapy
Departments in papersGastroenterology / hepatologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led12
  1. SND1-SMARCA5 interaction strengthened by PIM promotes the proliferation, metastasis, and chemoresistance of esophageal squamous cell carcinoma.2025International journal of biological macromolecules
  2. Esophageal cancer and precancerous lesions: focus on resident bacteria and fungi.2025Microbiology spectrumFree full text
  3. Non-endoscopic Screening for Esophageal Squamous Cell Carcinoma: Recent Advances.2024Journal of gastrointestinal cancer
  4. ML385 promotes ferroptosis and radiotherapy sensitivity by inhibiting the NRF2-SLC7A11 pathway in esophageal squamous cell carcinoma.2024Medical oncology (Northwood, London, England)Free full text
  5. Expression of Polyadenylate-binding Protein Cytoplasmic 1 (PABPC1) in Combination With RAD51 as Prognostic Biomarker in Patients Who Underwent Postoperative Chemotherapy for Esophageal Squamous Cell Carcinoma.2023Applied immunohistochemistry & molecular morphology : AIMM
  6. Metastasis to recurrent laryngeal nerve lymph nodes as a predictor of cervical lymph node metastasis in esophageal squamous cell carcinoma.2023Asian journal of surgery
  7. Engrailed 2 triggers the activation of multiple phosphorylation-induced signaling pathways in both transcription-dependent and -independent manners.2023Biochemical and biophysical research communications
  8. Hypoxia-responsive lncRNA G077640 promotes ESCC tumorigenesis via the H2AX-HIF1α-glycolysis axis.2023Carcinogenesis
  9. Circ_0024108 promotes the progression of esophageal cancer cells.2023General thoracic and cardiovascular surgery
  10. Erianin Exerts Antineoplastic Effects on Esophageal Squamous Cell Carcinoma Cells by Activating the cGMP-PKG Signaling Pathway.2023Nutrition and cancer
  11. KDM2A plays a dual role in regulating the expression of malignancy-related genes in esophageal squamous cell carcinoma.2022Biochemical and biophysical research communications
  12. CircRNA circ_0023984 promotes the progression of esophageal squamous cell carcinoma via regulating miR-134-5p/cystatin-s axis.2022BioengineeredFree full text
All its trials on ClinicalTrials.gov, any status1
  1. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
More papers found outside PubMed (not counted)12
  1. 253. MICROBIOTA ENTEROTOXIGENIC BACTEROIDES FRAGILIS (ETBF) PROMOTES ESCC TUMOR FORMATION, MIGRATION, AND INVASION BY PROMOTING EMT AND ACTIVATING TLR4/NF-κB SIGNALING PATHWAY2025Diseases of the Esophagusarticle
  2. 271O Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  3. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncologyconference-abstract
  4. Long-term survival of esophageal squamous cell carcinoma after surgical treatment in a large-scale retrospective study from a single cancer center2023Holistic Integrative Oncologyarticle
  5. Overexpression of CXCL5 promotes proliferation and infiltration of esophageal squamous cell carcinoma2023Research Squarepreprint
  6. 629 IRRADIATED ESOPHAGEAL SQUAMOUS CELL CARCINOMA CELLS INDUCED THE INCREASE OF TREG BY TGF-β2021Diseases of the Esophagusarticle
  7. 631 CLINICAL APPLICATION VALUE OF THE SYSTEMIC-IMMUNE-INFLAMMATION-INDEX FOR PREDICTING SURVIVAL IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA UNDERGOING CHEMORADIOTHERAPY OR RADIOTHERAPY2021Diseases of the Esophagusarticle
  8. 685 THE IMPACT OF ADJUVANT THERAPY ON SURVIVAL FOR NODE-NEGATIVE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PROPENSITY SCORE MATCHED ANALYSIS2021Diseases of the Esophagusarticle
  9. 695 METASTASIS OF THORACIC RECURRENT LARYNGEAL NERVE LYMPH NODE AS PREDICTOR FOR CERVICAL LYMPH NODE DISSECTION IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA2021Diseases of the Esophagusarticle
  10. KDM6B Promotes ESCC Cell Proliferation and Metastasis by Facilitating C/EBPβ Transcription2021Research Squarepreprint
  11. Long non-coding RNA BCAR4 aggravated proliferation and migration in esophageal squamous cell carcinoma by negatively regulating p53/p21 signaling pathway2021Figsharedataset
  12. MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 97 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
97
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 9920212022: 242420222023: 252520232024: 202020242025: 19192025

1 hospital in Luzhou for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  2. Recruiting
    GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2021-09
    Registry
    NCT05047510

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesLuzhou, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersMedical oncologySurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineRadiology / nuclear medicine
Papers it led97
  1. Synthesis and antitumor evaluation of glycyrrhetinic acid-dithiocarbamate hybrids.2025Archiv der Pharmazie
  2. Prediction model establishment of prognosis factors for distant metastasis of hepatocellular carcinoma based on the SEER database.2025Cancer epidemiology
  3. WWP2-induced inhibition of hepatocellular carcinoma cellular senescence via the ubiquitination and degradation of p21.2025Cell death & diseaseFree full text
  4. Lasso-Cox interpretable model of AFP-negative hepatocellular carcinoma.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  5. Icaritin-Loaded Liposomes Mediated by Hyaluronic Acid Promoted the Anti-Proliferation and Senescence in Huh7 Cells.2025Drug development research
  6. ANG secretion predisposes endothelial cells toward angiogenesis in FIN56-induced ferroptotic hepatocellular carcinoma via the BMP6/ID1 signaling pathway.2025Free radical biology & medicine
  7. ARIH2 serves as a potential prognostic biomarker for hepatocellular carcinoma associated with immune infiltration and ferroptosis.2025Frontiers in immunologyFree full text
  8. Emerging insights into the gut microbiota as a key regulator of immunity and response to immunotherapy in hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  9. Machine Learning-Based Integration of Single-Cell and Bulk Transcriptome Reveals Coagulation Signature and Phenotypic Heterogeneity in Hepatocellular Carcinoma.2025IET systems biologyFree full text
  10. Risk factors and clinical outcomes in patients with HCV eradication by direct-acting antivirals: a systematic review and meta-analysis.2025Infectious diseases (London, England)
  11. The Radiosensitizing Effect of Tumor-Derived Microparticles Co-Loaded with Sorafenib and Gold Nanoparticles on Hepatocellular Carcinoma.2025International journal of nanomedicineFree full text
  12. Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study.2025Investigational new drugsFree full text
  13. Letter to the editor comments on 'PBK as a Novel Biomarker with Excellent Diagnostic and Prognostic Value in HCC Associated with Immune Infiltration and Methylation'.2025Journal of molecular histologyFree full text
  14. HDAC2-mediated chromatin remodeling drives hepatocellular carcinoma progression: an integrative analysis of computational pathology and multi-transcriptomics.2025Journal of translational medicineFree full text
  15. ANXA2 in hepatocellular carcinoma: orchestrating tumorigenesis, progression, and therapeutic resistance toward precision targeting.2025Journal of translational medicineFree full text
  16. Asiaticoside enhances the anti-tumor effect of anti-PDL1 by regulating T cell activity through increasing LCK activity.2025Pathology, research and practice
  17. Escin inhibits PD-L1 expression by suppressing the p38 MAPK/ERK signalling pathways and synergistically enhances PD-1 inhibitor efficacy in hepatocellular carcinoma.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  18. Asparagine synthetase modulates glutaminase inhibitor sensitivity through metabolic reprogramming and serves as a prognostic biomarker in hepatocellular carcinoma.2025Redox biologyFree full text
  19. Primary Pulmonary Osteosarcoma Presenting as a 1.7-cm Subpleural Nodule in a 61-Year-Old Man: A Case Report.2025The American journal of case reportsFree full text
  20. PART1 facilitates tumorigenesis and inhibits ferroptosis by regulating the miR-490-3p/SLC7A11 axis in hepatocellular carcinoma.2024AgingFree full text
  21. GLO1 regulates hepatocellular carcinoma proliferation and migration through the cell cycle pathway.2024BMC cancerFree full text
  22. CT radiomics based on different machine learning models for classifying gross tumor volume and normal liver tissue in hepatocellular carcinoma.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  23. Integration of single-cell and bulk RNA-sequencing to analyze the heterogeneity of hepatocellular carcinoma and establish a prognostic model.2024Cancer reports (Hoboken, N.J.)Free full text
  24. Identification of formononetin as the active compound of CR-SR in hepatocellular carcinoma treatment: An integrated approach combining network pharmacology and weighted gene co-expression networks.2024Chemical biology & drug design
  25. Biomimetic platelet-like nanoparticles enhance targeted hepatocellular carcinoma therapy.2024Colloids and surfaces. B, Biointerfaces
  26. Integrative analysis revealed a correlation of PIAS family genes expression with prognosis, immunomodulation and chemotherapy.2024European journal of medical researchFree full text
  27. PRMT1-mediated arginine methylation promotes YAP activation and hepatocellular carcinoma proliferation.2024FEBS open bioFree full text
  28. Role and therapeutic potential of E3s in the tumor microenvironment of hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  29. Extracellular vesicles in hepatocellular carcinoma: unraveling immunological mechanisms for enhanced diagnosis and overcoming drug resistance.2024Frontiers in immunologyFree full text
  30. Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances.2024Frontiers in immunologyFree full text
  31. Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma.2024Immunology
  32. A pH-Responsive Drug-Delivery System Based on Apatinib-Loaded Metal-Organic Frameworks for Ferroptosis-Targeted Synergistic Anti-Tumor Therapy.2024International journal of nanomedicineFree full text
  33. Association between antithrombotic agents use and hepatocellular carcinoma risk: a two-sample mendelian randomization analysis.2024Journal of cancer research and clinical oncologyFree full text
  34. Cholecystohepatic shunt pathway reduces secondary bile acid accumulation to enhance natural killer T cell-mediated anti-hepatocellular carcinoma immunity.2024Journal of gastroenterology and hepatology
  35. Circular RNA ACVR2A promotes the progression of hepatocellular carcinoma through mir-511-5p targeting PI3K-Akt signaling pathway.2024Molecular cancerFree full text
  36. Effect of cytokines on advanced hepatocellular carcinoma prognosis receiving radiotherapy and tislelizumab plus anlotinib: a single-center phase II clinical trial.2024Scientific reportsFree full text
  37. FXR, MRP-1 and SLC7A5: New Targets for the Treatment of Hepatocellular Carcinoma.2024Technology in cancer research & treatmentFree full text
  38. Obesity phenotype induced by high-fat diet promotes diethylnitrosamine (DEN)-induced precancerous lesions by M1 macrophage polarization in mice liver.2024The Journal of nutritional biochemistry
  39. Potential applications of dual haptoglobin expression in the reclassification and treatment of hepatocellular carcinoma.2024Translational research : the journal of laboratory and clinical medicine
  40. Autophagy-Targeted Calcium Phosphate Nanoparticles Enable Transarterial Chemoembolization for Enhanced Cancer Therapy.2023ACS applied materials & interfaces
  41. TMX family genes and their association with prognosis, immune infiltration, and chemotherapy in human pan-cancer.2023AgingFree full text
  42. Construction and validation of a nomogram for HBV-related hepatocellular carcinoma: A large, multicenter study.2023Annals of hepatologyRCT
  43. Transhepatectomy combined with arterial chemoembolization and transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a clinical prognostic analysis.2023BMC gastroenterologyFree full text
  44. A new prediction model of hepatocellular carcinoma based on N7-methylguanosine modification.2023BMC gastroenterologyFree full text
  45. Chemical profiling and investigation of molecular mechanisms underlying anti-hepatocellular carcinoma activity of extracts from Polygonum perfoliatum L.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  46. Integrated bulk and single-cell transcriptomes reveal pyroptotic signature in prognosis and therapeutic options of hepatocellular carcinoma by combining deep learning.2023Briefings in bioinformaticsFree full text
  47. The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma.2023Cancer immunology, immunotherapy : CIIFree full text
  48. External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.2023Clinical and experimental medicineFree full text
  49. Comparison of the efficacy and safety of selective internal radiotherapy and sorafenib alone or combined for hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis.2023Clinical and experimental medicineFree full text
  50. FANCD2 as a novel prognostic biomarker correlated with immune and drug therapy in Hepatitis B-related hepatocellular carcinoma.2023European journal of medical researchFree full text
  51. Understanding sorafenib-induced ferroptosis and resistance mechanisms: Implications for cancer therapy.2023European journal of pharmacology
  52. Effect of external beam radiation therapy versus transcatheter arterial chemoembolization for non-diffuse hepatocellular carcinoma (≥ 5 cm): a multicenter experience over a ten-year period.2023Frontiers in immunologyFree full text
  53. T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis via integrating single-cell RNA-seq and bulk RNA-sequencing.2023Frontiers in immunologyFree full text
  54. Construction of Curcumin and Paclitaxel Co-Loaded Lipid Nano Platform and Evaluation of Its Anti-Hepatoma Activity in vitro and Pharmacokinetics in vivo.2023International journal of nanomedicineFree full text
  55. Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives m62A and CD) regulations on patients with cancer and healthy individuals.2023International journal of oncologyFree full text
  56. A commentary on 'Laparoscopic versus open liver resection for hepatocellular carcinoma in elderly patients: Systematic review and meta-analysis of propensity-score matched studies' [Int J Surg 105 (2022) 106821].2023International journal of surgery (London, England)Free full text
  57. Multifunctional nanoplatforms application in the transcatheter chemoembolization against hepatocellular carcinoma.2023Journal of nanobiotechnologyFree full text
  58. Zyxin promotes hepatocellular carcinoma progression via the activation of AKT/mTOR signaling pathway.2023Oncology researchFree full text
  59. Deciphering the tumour immune microenvironment of hepatocellular carcinoma.2023Scandinavian journal of immunology
  60. Integrated analysis of histone lysine lactylation (Kla)-specific genes suggests that NR6A1, OSBP2 and UNC119B are novel therapeutic targets for hepatocellular carcinoma.2023Scientific reportsFree full text
  61. A propensity score matching study on survival benefits of radiotherapy in patients with inoperable hepatocellular carcinoma.2023Scientific reportsFree full text
  62. α-LA attenuates microcystin-LR-induced hepatocellular oxidative stress in mice through Nrf2-mediated antioxidant and detoxifying enzymes.2023Toxicon : official journal of the International Society on Toxinology
  63. Construction of a diagnostic model for hepatitis B-related hepatocellular carcinoma using machine learning and artificial neural networks and revealing the correlation by immunoassay.2023Tumour virus researchFree full text
  64. Treatments for recurrent hepatocellular carcinoma: laparoscopic or open repeat liver resection, how to make a decision?2023Updates in surgeryFree full text
  65. THRSP identified as a potential hepatocellular carcinoma marker by integrated bioinformatics analysis and experimental validation.2022AgingFree full text
  66. Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis.2022Annals of hepatology
  67. CircSEC24A (hsa_circ_0003528) interference suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells via miR-421/MMP3 axis.2022BioengineeredFree full text
  68. Unbalanced Glutamine Partitioning between CD8T Cells and Cancer Cells Accompanied by Immune Cell Dysfunction in Hepatocellular Carcinoma.2022CellsFree full text
  69. LRFNet: A deep learning model for the assessment of liver reserve function based on Child-Pugh score and CT image.2022Computer methods and programs in biomedicine
  70. Integrated transcriptomics unravels implications of glycosylation-regulating signature in diagnosis, prognosis and therapeutic benefits of hepatocellular carcinoma.2022Computers in biology and medicine
  71. Roles of M6A Regulators in Hepatocellular Carcinoma: Promotion or Suppression.2022Current gene therapy
  72. Exosomal Non-Coding RNAs: New Insights into the Biology of Hepatocellular Carcinoma.2022Current oncology (Toronto, Ont.)Free full text
  73. Intraperitoneal administration of thermosensitive hydrogel Co-loaded with norcantharidin nanoparticles and oxaliplatin inhibits malignant ascites of hepatocellular carcinoma.2022Drug deliveryFree full text
  74. Partial hepatectomy vs. transcatheter arterial chemoembolization for multiple hepatocellular carcinomas of BCLC-B stage: A meta-analysis of high-quality studies.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  75. Obeticholic acid and 5β-cholanic acid 3 exhibit anti-tumor effects on liver cancer through CXCL16/CXCR6 pathway.2022Frontiers in immunologyFree full text
  76. PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study.2022Frontiers in immunologyFree full text
  77. Heat-shock protein 90α is a potential prognostic and predictive biomarker in hepatocellular carcinoma: a large-scale and multicenter study.2022Hepatology internationalFree full text
  78. Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study.2022Hepatology internationalFree full text
  79. Hepatitis B virus X protein mediated epigenetic alterations in the pathogenesis of hepatocellular carcinoma.2022Hepatology international
  80. The efficacy of transarterial chemoembolization in downstaging unresectable hepatocellular carcinoma to curative therapy: a predicted regression model.2022Investigational new drugs
  81. The lncARSR/PTEN/Akt/nuclear factor-kappa B feedback regulatory loop contributes to doxorubicin resistance in hepatocellular carcinoma.2022Journal of biochemical and molecular toxicology
  82. Development of a Hepatic VX2 carcinoma model in rabbits using an improved minimally invasive method and evaluation with imaging examinations.2022Journal of cancer research and therapeutics
  83. LncRNA NCK1-AS1 Aggravates Hepatocellular Carcinoma by the miR-22-3p/YARS Axis to Activate PI3K/AKT Signaling.2022Journal of gastrointestinal and liver diseases : JGLD
  84. Uncovering the Mechanisms of Active Components from Toad Venom against Hepatocellular Carcinoma Using Untargeted Metabolomics.2022Molecules (Basel, Switzerland)Free full text
  85. Pathological images for personal medicine in Hepatocellular carcinoma: Cross-talk of gene sequencing and pathological images.2022Oncology researchFree full text
  86. Alnustone inhibits the growth of hepatocellular carcinoma via ROS- mediated PI3K/Akt/mTOR/p70S6K axis.2022Phytotherapy research : PTR
  87. The relationship between NTCP gene varieties and the progress of liver disease after HBV infection: an updated systematic review and meta-analysis.2022The American journal of the medical sciences
  88. The Biomarkers for Predicting Viral HepatitisAssociated Hepatocellular Carcinoma.2022The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  89. Inflow vascular occlusion technique versus hemihepatic vascular maneuver in hepatectomy: A systematic review and meta-analysis.2021Asian journal of surgery
  90. Predictive factors for survival following stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumour thrombosis and construction of a nomogram.2021BMC cancerFree full text
  91. miR-381 Reverses Multidrug Resistance by Negative Regulation of the CTNNB1/ABCB1 Pathway in HepG2/Dox Cells, and the Diagnostic and Prognostic Values of CTNNB1/ABCB1 Are Identified in Patients with LIHC.2021DNA and cell biology
  92. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.2021Frontiers in immunologyFree full text
  93. Long Non-Coding RNAs: Potential Biomarkers and Targets for Hepatocellular Carcinoma Therapy and Diagnosis.2021International journal of biological sciencesFree full text
  94. Intratumoral Administration of Thermosensitive Hydrogel Co-Loaded with Norcantharidin Nanoparticles and Doxorubicin for the Treatment of Hepatocellular Carcinoma.2021International journal of nanomedicineFree full text
  95. FBXL19-AS1 aggravates the progression of hepatocellular cancer by downregulating KLF2.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  96. Early versus Delayed Hepatectomy for Spontaneously Ruptured Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.2021Journal of investigative surgery : the official journal of the Academy of Surgical Research
  97. Long noncoding RNAs as biomarkers for the diagnosis of hepatocellular carcinoma: A meta-analysis.2021Pathology, research and practice
Chinese-language papers (not in the count)2
  1. [Silencing SIRT1 reduces 5-fluorouracil resistance of cholangiocarcinoma cells by inhibiting the FOXO1/Rab7 autophagy pathway].2023Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  2. [MicroRNA 424-5p promotes the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting Kinesin family member 23].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status4
  1. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  2. GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular CarcinomaRecruitingNCT05047510Study siteN/AStart 2021-09
  3. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphereActive, not recruitingNCT06900543Study sitePhase 3Start 2025-04
  4. Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular CarcinomaCompletedNCT06310590Study sitePhase 1Start 2023-08

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 39 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.4%.

Papers led
39
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 7720212022: 5520222023: 111120232024: 121220242025: 332025

1 hospital in Luzhou for stomach cancer211 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunotherapy & targeted drugsImaging & AIEarly detection & endoscopy
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led39
  1. The impact of multidimensional interactions among Helicobacter pylori infection, tumor microenvironment, and gut microbiota on gastric cancer immune response.2026European journal of pharmacology
  2. Mechanisms and therapeutic strategies to reveal and overcome T-cell dysfunction in gastric cancer: translation from basic research to clinical application.2025Frontiers in immunologyFree full text
  3. Glucose metabolism reprogramming in gastric cancer: Implications for tumor.2025International immunopharmacology
  4. Expression, regulation, function and clinical significance of B7-H6 on neutrophils in human gastric cancer.2025Neoplasia (New York, N.Y.)Free full text
  5. Identification of immunotherapy-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognostic signature in gastric carcinoma.2024AgingFree full text
  6. Downregulation of PDIA3 inhibits gastric cancer cell growth through cell cycle regulation.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  7. Deep learning is necessary for safety regulation in predicting malnutrition in gastric cancer patients.2024Clinical nutrition (Edinburgh, Scotland)
  8. eIF6 Promotes Gastric Cancer Proliferation and Invasion by Regulating Cell Cycle.2024Digestive diseases and sciencesFree full text
  9. Dysregulation of systemic immunity and its clinical application in gastric cancer.2024Frontiers in immunologyFree full text
  10. Letter to the Editor for the article 'A nomogram incorporating treatment data for predicting overall survival in gastroenteropancreatic neuroendocrine tumors: a population-based cohort study'.2024International journal of surgery (London, England)Free full text
  11. Tumor-infiltrating mast cells stimulate ICOS+ regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression.2024Journal of advanced researchFree full text
  12. Cause of death among gastric cancer survivors in the United States from 2000 to 2020.2024MedicineFree full text
  13. LncRNA RP11-93B14.5 promotes gastric cancer cell growth through PI3K/AKT signaling pathway.2024Molecular biotechnology
  14. Circadian rhythm genes contribute to the prognosis prediction and potential therapeutic target in gastric cancer.2024Scientific reportsFree full text
  15. Development of a CD8+ T cell associated signature for predicting the prognosis and immunological characteristics of gastric cancer by integrating single-cell and bulk RNA-sequencing.2024Scientific reportsFree full text
  16. Supradiaphragmatic Gastric Monodermal Teratoma With Bronchus-Like Structures.2024The American journal of gastroenterology
  17. Pulling out the radish without mud: Endoscopic blunt dissection of a gastric submucosal tumor.2023Asian journal of surgery
  18. The effect of liver transplantation on gastric cancer: A meta-analysis.2023Asian journal of surgery
  19. Gastric cancer incidence trends in China and Japan from 1990 to 2019: Disentangling age-period-cohort patterns.2023Cancer
  20. miR-199a-3p promotes gastric cancer progression by promoting its stemness potential via DDR2 mediation.2023Cellular signalling
  21. Giant gastric myxoid epithelioid gastrointestinal stromal tumor.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  22. Dual-Regulated Mechanism of EZH2 and KDM6A on SALL4 Modulates Tumor Progression via Wnt/β-Catenin Pathway in Gastric Cancer.2023Digestive diseases and sciences
  23. Cd44v6 acts as a directional responding factor in the process of transcoelomic metastasis from gastric carcinoma to Krukenberg tumor.2023Expert review of molecular diagnostics
  24. SDPR Inhibits TGF-β Induced Cancer Metastasis Through Fatty Acid Oxidation Regulation in Gastric Cancer.2023International journal of biological sciencesFree full text
  25. Endoscopic Removal of an Embedded Fishbone in the Gastric Antrum.2023Journal of gastrointestinal and liver diseases : JGLD
  26. Gender authorship trends of gastric cancer in the top journals of gastroenterology: A 20-year perspective.2023MedicineFree full text
  27. Association between blood lipid levels and risk of gastric cancer: A systematic review and meta-analysis.2023PloS oneFree full text
  28. FasL+ PD-L2+ Identifies a Novel Immunosuppressive Neutrophil Population in Human Gastric Cancer That Promotes Disease Progression.2022Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  29. Reverse rolling-mat type lymph node dissection is the key step to solve the operative difficulties in hand-assisted laparoscopic D2 radical gastrectomy.2022BMC surgeryFree full text
  30. Gastric cancer incidence, mortality and burden in adolescents and young adults: a time-trend analysis and comparison among China, South Korea, Japan and the USA.2022BMJ openFree full text
  31. The Role of Vitamin D in Gastrointestinal Diseases: Inflammation, Gastric Cancer, and Colorectal Cancer.2022Current medicinal chemistry
  32. H19 may regulate the immune cell infiltration in carcinogenesis of gastric cancer through miR-378a-5p/SERPINH1 signaling.2022World journal of surgical oncologyFree full text
  33. Identifying Novel Cell Glycolysis-Related Gene Signature Predictive of Overall Survival in Gastric Cancer.2021BioMed research internationalFree full text
  34. Developing a risk scoring system based on immune-related lncRNAs for patients with gastric cancer.2021Bioscience reportsFree full text
  35. Activated neutrophils polarize protumorigenic interleukin-17A-producing T helper subsets through TNF-α-B7-H2-dependent pathway in human gastric cancer.2021Clinical and translational medicineFree full text
  36. Expression, regulation and clinical significance of B7-H3 on neutrophils in human gastric cancer.2021Clinical immunology (Orlando, Fla.)
  37. The Multifaceted Role of Long Non-Coding RNA in Gastric Cancer: Current Status and Future Perspectives.2021International journal of biological sciencesFree full text
  38. Vitamin D suppressed gastric cancer cell growth through downregulating CD44 expression in vitro and in vivo.2021Nutrition (Burbank, Los Angeles County, Calif.)
  39. The distinct roles of exosomes in tumor-stroma crosstalk within gastric tumor microenvironment.2021Pharmacological research
Chinese-language papers (not in the count)1
  1. [The feasibility analysis of multi-slice spiral CT features of gastric stromal tumors in predicting pathological National Institutes of Health risk classification].2022Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status1
  1. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Luzhou for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine
Papers it led1
  1. Detection of Parotid Metastasis from Retinoblastoma by 18F-FDG PET/CT scan.2022Revista espanola de medicina nuclear e imagen molecular

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Luzhou for chordoma84 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 20 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
20
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 1120222023: 3320232024: 6620242025: 662025

2 hospitals in Luzhou for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyPediatricsRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led20
  1. KC1036 in ewing sarcoma: mechanistic insights and future directions for a multi-targeted therapeutic strategy.2025Angiogenesis
  2. Incidence trends, overall survival, and metastasis prediction using multiple machine learning and deep learning techniques in pediatric and adolescent population with osteosarcoma and Ewing's sarcoma: nomogram and webpage.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  3. Challenges in Diagnosing Primary Intracranial Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor: A Case Report.2025Current medical imaging
  4. KIAA1429 as a therapeutic target in osteosarcoma: challenging the linear ferroptosis pathway and evaluating translational hurdles.2025Inflammation research : official journal of the European Histamine Research Society ... [et al.]
  5. Plasma proteins and osteosarcoma: Mendelian randomization analysis and targeted therapeutic discovery.2025Medicine
  6. Primary Pulmonary Osteosarcoma Presenting as a 1.7-cm Subpleural Nodule in a 61-Year-Old Man: A Case Report.2025The American journal of case reportsFree full text
  7. Ubiquitination in osteosarcoma: unveiling the impact on cell biology and therapeutic strategies.2024Cancer biology & medicine
  8. Mefenamic acid exhibits antitumor activity against osteosarcoma by impeding cell growth and prompting apoptosis in human osteosarcoma cells and xenograft mice model.2024Chemico-biological interactions
  9. Investigating the molecular mechanism of Mori Cortex against osteosarcoma by bioinformatics analysis and in vitro experimental.2024Medicine
  10. Honokiol inhibits human osteosarcoma MG63 cell migration by upregulating FTO and Smad6 to promote autophagy.2024Molecular and cellular probes
  11. Circular RNA IARS modulates the progression and ferroptosis of osteosarcoma via sponging miR-188-5p from RAB14.2024Neoplasma
  12. Tumor-derived microparticles promoted M2-like macrophages polarization to stimulate osteosarcoma progression.2024The international journal of biochemistry & cell biology
  13. The Long Noncoding RNA ZEB2-AS1 Contributes to Proliferation and Epithelial-to-Mesenchymal Transition of Osteosarcoma.2023Cancer biotherapy & radiopharmaceuticals
  14. ITGB3 promotes cisplatin resistance in osteosarcoma tumors.2023Cancer medicine
  15. Identification of genes contributing to cisplatin resistance in osteosarcoma cells.2023FEBS open bio
  16. Hox transcript antisense RNA knockdown inhibits osteosarcoma progression by regulating the phosphoinositide 3-kinase/AKT pathway through the microRNA miR-6888-3p/spleen tyrosine kinase axis.2022Bioengineered
  17. TGF-β protects osteosarcoma cells from chemotherapeutic cytotoxicity in a SDH/HIF1α dependent manner.2021BMC cancer
  18. Long non-coding RNA (LncRNA) MRPL23-AS1 promotes tumor progression and carcinogenesis in osteosarcoma by activating Wnt/β-catenin signaling via inhibiting microRNA miR-30b and upregulating myosin heavy chain 9 (MYH9).2021Bioengineered
  19. Codelivery of survivin inhibitor and chemotherapeutics by tumor-derived microparticles to reverse multidrug resistance in osteosarcoma.2021Cell biology international
  20. Limb-salvage surgery using personalized 3D-printed porous tantalum prosthesis for distal radial osteosarcoma: A case report.2021Medicine
Earlier papers (2016–2020)6
  1. LncRNA FER1L4 induces apoptosis and suppresses EMT and the activation of PI3K/AKT pathway in osteosarcoma cells via inhibiting miR-18a-5p to promote SOCS5.2019Gene
  2. Screening candidate microRNA-mRNA network for predicting the response to chemoresistance in osteosarcoma by bioinformatics analysis.2019Journal of cellular biochemistry
  3. The relationship between the expression of TAM, survivin and the degree of necrosis of the tumor after cisplatin treatment in osteosarcoma.2017European review for medical and pharmacological sciences
  4. LncRNA SOX2-OT is a novel prognostic biomarker for osteosarcoma patients and regulates osteosarcoma cells proliferation and motility through modulating SOX2.2017IUBMB life
  5. The clinical significance of neoadjuvant chemotherapy in improving the drug resistance of osteosarcoma.2017Minerva medica
  6. The metastasis suppressor gene KISS-1 regulates osteosarcoma apoptosis and autophagy processes.2017Molecular medicine reports

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Luzhou for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicine
Papers it led1
  1. Giant gastric myxoid epithelioid gastrointestinal stromal tumor.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Chinese-language papers (not in the count)1
  1. [The feasibility analysis of multi-slice spiral CT features of gastric stromal tumors in predicting pathological National Institutes of Health risk classification].2022Zhonghua yi xue za zhi
Earlier papers (2016–2020)1
  1. Traction with snare during endoscopic submucosal dissection of a gastrointestinal stromal tumor in the gastric fundus.2016Endoscopy

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Luzhou for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgery

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 3 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.8%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 332025

1 hospital in Luzhou for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 10 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.6%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 4420222023: 4420232024: 1120242025: 112025

1 hospital in Luzhou for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskDrug combinationsKidney & bone complications
Departments in papersNephrologyRadiology / nuclear medicine
Papers it led10
  1. Decreased STING predicts adverse efficacy in bortezomib regimens and poor survival in multiple myeloma.2025Clinical and experimental medicineFree full text
  2. The effect of immunomodulatory drugs on bone metabolism of patients with multiple myeloma.2024Expert review of hematology
  3. 18F‑FDG PET/CT based radiomics features improve prediction of prognosis: multiple machine learning algorithms and multimodality applications for multiple myeloma.2023BMC medical imagingFree full text
  4. Repurposing Metformin in hematologic tumor: State of art.2023Current problems in cancer
  5. Non-crystalline light chain proximal tubular disease associated with Waldenström macroglobulinemia.2023International urology and nephrology
  6. LAMP5 may promote MM progression by activating p38.2023Pathology oncology research : PORFree full text
  7. Is RDW a clinically relevant prognostic factor for newly diagnosed multiple myeloma? A systematic review and meta-analysis.2022BMC cancerFree full text
  8. The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG.2022European journal of nuclear medicine and molecular imaging
  9. The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis.2022European review for medical and pharmacological sciences
  10. Serum metabolomics reveals the effects of accompanying treatment on fatigue in patients with multiple myeloma.2022Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
All its trials on ClinicalTrials.gov, any status1
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 2 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Luzhou for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesStem cell transplantPhiladelphia chromosome & genetics
Departments in papersPediatricsMedical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 2 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

1 hospital in Luzhou for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 3 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 1.0%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 0020242025: 002025

1 hospital in Luzhou for beta thalassaemia133 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Luzhou for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 3 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 1.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Luzhou for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Luzhou for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Hepatic echinococcosis

肝包虫病

Led 1 of the 152 English-language PubMed papers on hepatic echinococcosis with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Luzhou for hepatic echinococcosis44 hospitals in China for hepatic echinococcosis

No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Luzhou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led 1 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 2.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Luzhou for lymphangioleiomyomatosis27 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Papers it led1
  1. Incidental lymphangioleiomyomatosis in pelvic lymph nodes associated with Malignant neoplasm of the ovary - two case reports.2023Polish journal of pathology : official journal of the Polish Society of Pathologists

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Luzhou for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Luzhou for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led 1 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Luzhou for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 3 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.4%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 0020242025: 002025

2 hospitals in Luzhou for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Nephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Luzhou for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Luzhou for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 2 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 3.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

1 hospital in Luzhou for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

西南医科大学附属医院

Affiliated Hospital of Southwest Medical University

泸州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Southwest Medical University; Affiliated Hospital of South West Medical University; Affliated Hospital of Southwest Medical University; First Affiliated Hospital of Southwest Medical University; Affiliated Hospital of SouthWest Medical University; Hospital (T.C.M) Affiliated to Southwest Medical University; Affiliated to Southwest Medical University; Affiliated TCM Hospital of Southwest Medical University

Suggest a correctionDownload the data